AMEX:XTNT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. More Details


Snowflake Analysis

Weak fundamentals or lack of information.


Similar Companies

Share Price & News

How has Xtant Medical Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XTNT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.5%

XTNT

-2.5%

US Medical Equipment

-3.1%

US Market


1 Year Return

-67.8%

XTNT

14.6%

US Medical Equipment

12.7%

US Market

Return vs Industry: XTNT underperformed the US Medical Equipment industry which returned 15.2% over the past year.

Return vs Market: XTNT underperformed the US Market which returned 12.9% over the past year.


Shareholder returns

XTNTIndustryMarket
7 Day-8.5%-2.5%-3.1%
30 Day-10.4%-0.06%-2.9%
90 Day-20.1%13.9%8.2%
1 Year-67.8%-67.8%15.6%14.6%15.3%12.7%
3 Year-90.6%-90.6%71.4%67.0%37.8%28.5%
5 Year-98.1%-98.1%149.1%130.4%90.9%69.4%

Price Volatility Vs. Market

How volatile is Xtant Medical Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Xtant Medical Holdings undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Xtant Medical Holdings is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Xtant Medical Holdings has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of XTNT's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Xtant Medical Holdings regulatory filings.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Xtant Medical Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-59.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XTNT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XTNT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XTNT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XTNT's revenue (8.6% per year) is forecast to grow slower than the US market (9.8% per year).

High Growth Revenue: XTNT's revenue (8.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XTNT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Xtant Medical Holdings performed over the past 5 years?

-24.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XTNT is currently unprofitable.

Growing Profit Margin: XTNT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XTNT is unprofitable, and losses have increased over the past 5 years at a rate of 24.1% per year.

Accelerating Growth: Unable to compare XTNT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XTNT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: XTNT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Xtant Medical Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: XTNT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: XTNT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: XTNT has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: XTNT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XTNT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: XTNT has less than a year of cash runway if free cash flow continues to grow at historical rates of 27% each year.


Next Steps

Dividend

What is Xtant Medical Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XTNT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XTNT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XTNT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XTNT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XTNT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Sean Browne (54 yo)

0.92

Tenure

US$2,241,630

Compensation

Mr. Sean E. Browne serves as President and Chief Executive Officer of Xtant Medical Holdings, Inc. since October 7, 2019 and its Director since October 30, 2019. Mr. Browne has been Chief Revenue Officer a ...


CEO Compensation Analysis

Compensation vs Market: Sean's total compensation ($USD2.24M) is above average for companies of similar size in the US market ($USD589.04K).

Compensation vs Earnings: Insufficient data to compare Sean's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Sean Browne
President0.92yrUS$2.24mno data
Greg Jensen
VP of Finance & CFO1.58yrsUS$719.77k0.064%
$ 7.0k
Kevin Brandt
Senior VP & Chief Commercial Officer2.17yrsUS$812.27k0.066%
$ 7.2k
Catherine Lundy
Vice President of Human Resources6yrsno datano data
Kevin O'Dare
Vice President of Sales - Eastern US5.83yrsUS$347.69kno data

2.2yrs

Average Tenure

54yo

Average Age

Experienced Management: XTNT's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sean Browne
President0.92yrUS$2.24mno data
John Bakewell
Independent Director2.58yrsUS$90.15k0.24%
$ 26.0k
Jeffrey Peters
Chairman of the Board2.58yrsUS$90.15k0.24%
$ 26.0k
Robert McNamara
Independent Director2.58yrsUS$99.03k0.23%
$ 24.6k
Matthew Rizzo
Director2.58yrsUS$93.33kno data
Michael Eggenberg
Director2.58yrsUS$93.33kno data

2.6yrs

Average Tenure

52.5yo

Average Age

Experienced Board: XTNT's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Xtant Medical Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Xtant Medical Holdings, Inc.
  • Ticker: XTNT
  • Exchange: AMEX
  • Founded:
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$10.900m
  • Shares outstanding: 13.24m
  • Website: https://www.xtantmedical.com

Number of Employees


Location

  • Xtant Medical Holdings, Inc.
  • 664 Cruiser Lane
  • Belgrade
  • Montana
  • 59714
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XTNTAMEX (NYSE MKT LLC)YesCommon StockUSUSDJul 2010
XMSDB (Deutsche Boerse AG)YesCommon StockDEEURJul 2010

Biography

Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its bi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/22 06:10
End of Day Share Price2020/09/21 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.